June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Phase I/IIa clinical trial of human embryonic stem cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen®) transplantation in advanced dry form age-related macular degeneration (AMD): interim results
Author Affiliations & Notes
  • Eyal Banin
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Yitzchak Hemo
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Tareq Jaouni
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Devora Marks-Ohana
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Shelly Stika
    Cell Cure Neurosciences Ltd, Jerusalem, Israel
  • Svetlana Zheleznykov
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Alexey Obolensky
    Center for Retinal and Macular Degenerations, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Maria Gurevich
    Cell Cure Neurosciences Ltd, Jerusalem, Israel
  • Charles S/ Irving
    Cell Cure Neurosciences Ltd, Jerusalem, Israel
  • Benjamin Reubinoff
    Center for Embryonic Stem Cells and the Department of Gynecology and Obstetrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
  • Footnotes
    Commercial Relationships   Eyal Banin, Cell Cure Neurosciences (C), Cell Cure Neurosciences (P); Yitzchak Hemo, Cell Cure Neurosciences (P); Tareq Jaouni, None; Devora Marks-Ohana, None; Shelly Stika, None; Svetlana Zheleznykov, None; Alexey Obolensky, Cell Cure Neurosciences (P); Maria Gurevich, Cell Cure Neurosciences (E); Charles Irving, Cell Cure Neurosciences (E); Benjamin Reubinoff, Cell Cure Neuroscience (F), Cell Cure Neurosciences (C), Cell Cure Neurosciences (P)
  • Footnotes
    Support  Cell Cure Neurosciences and its grants from the Israel Innovation Authority
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2320. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Eyal Banin, Yitzchak Hemo, Tareq Jaouni, Devora Marks-Ohana, Shelly Stika, Svetlana Zheleznykov, Alexey Obolensky, Maria Gurevich, Charles S/ Irving, Benjamin Reubinoff; Phase I/IIa clinical trial of human embryonic stem cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen®) transplantation in advanced dry form age-related macular degeneration (AMD): interim results. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2320.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Transplantation studies using autologous RPE cells in AMD patients suggest that introducing healthy RPE cells may be of benefit. Over the last decade we developed the technology to derive RPE cells in-vitro from hESCs using a directed differentiation, xeno-free protocol. Safety and tolerability of this cell product, OpRegen, is now being evaluated in a dose-escalating Phase I/IIa clinical study in patients with advanced dry AMD accompanied by geographic atrophy (NCT02286089). Here we report accumulated safety and imaging data from the 1st and 2nd cohorts of patients, who received a subretinal transplant of 50k or 200k OpRegen cells in suspension, with up to 1 year follow up.

Methods : Transplantation was performed by subretinal injection following conventional 23G vitrectomy under local anesthesia. Systemic immunosuppression is administered from 1 week prior to transplantation until 1 year after. Systemic and ocular safety is closely monitored. Retinal function and structure are assessed using various techniques including BCVA, and color, OCT and fundus autofluorescence (FAF) imaging.

Results : At date of writing, dosing of cohort 1 of 3 patients (ages 74-80 years) who received 50k cells has been completed with a follow-up of 1 year, 9 and 6 months, and 2 out of 3 patients from cohort 2 (ages 65 and 82) were dosed with 200k cells. Surgery was uneventful, with subretinal fluid absorbing within <48 hours. OCT imaging showed healing of the retinal penetration site by 2 weeks post-op. Treatment has been well tolerated systemically and with regard to ocular findings. Imaging changes associated with OpRegen include subretinal pigmentation in area of transplant in 4 out of 5 patients, often accompanied by hypo- and hyper-fluorescent spots on FAF imaging and irregular reflectance above areas of atrophy and host RPE on OCT scans. These changes develop over the first 2-3 months and persist through the latest time point examined. Of note, epiretinal membranes that do not require surgical intervention were observed.

Conclusions : Subretinal transplantation of OpRegen in patients with advanced dry AMD appears well tolerated to date. Findings on imaging suggest presence of cells in the subretinal space. These results provide a framework for functional assessments in cohorts at higher doses.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×